Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2018
Price : $35 *
At a glance
- Drugs IGF-methotrexate (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors IGF Oncology
- 02 Apr 2018 Status changed from not yet recruiting to recruiting.
- 09 Nov 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
- 23 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.